Cargando…

Longitudinal Analysis of Disease Burden in Refractory and Nonrefractory Generalized Myasthenia Gravis in the United States

OBJECTIVE: To compare temporal trends in clinical and health care resource utilization (HRU) outcomes in people with refractory and nonrefractory generalized myasthenia gravis (gMG). METHODS: A retrospective analysis of data from adults with gMG in the Myasthenia Gravis Foundation of America Patient...

Descripción completa

Detalles Bibliográficos
Autores principales: Harris, Linda, Allman, Phillip H., Sheffield, Reinee, Cutter, Gary
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Journal of Clinical Neuromuscular Disease 2020
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7447171/
https://www.ncbi.nlm.nih.gov/pubmed/32833720
http://dx.doi.org/10.1097/CND.0000000000000301
_version_ 1783574250431447040
author Harris, Linda
Allman, Phillip H.
Sheffield, Reinee
Cutter, Gary
author_facet Harris, Linda
Allman, Phillip H.
Sheffield, Reinee
Cutter, Gary
author_sort Harris, Linda
collection PubMed
description OBJECTIVE: To compare temporal trends in clinical and health care resource utilization (HRU) outcomes in people with refractory and nonrefractory generalized myasthenia gravis (gMG). METHODS: A retrospective analysis of data from adults with gMG in the Myasthenia Gravis Foundation of America Patient Registry. gMG status (ever-refractory or always nonrefractory) and clinical (Myasthenia Gravis—Activities of Daily Living [MG-ADL] scores, exacerbations) and HRU outcomes were determined from questionnaires self-completed 6-monthly for up to 4 years. The probability of each outcome was compared for the 2 groups over time. RESULTS: The mean MG-ADL score and the probability of experiencing each outcome were significantly greater in the ever-refractory versus nonrefractory groups during each year of follow-up. Between-group differences in time trends were statistically significant for intensive care and feeding-tube use. CONCLUSIONS: People who have ever had refractory gMG may have worse functional status, more exacerbations, and higher HRU than people with consistently nonrefractory disease.
format Online
Article
Text
id pubmed-7447171
institution National Center for Biotechnology Information
language English
publishDate 2020
publisher Journal of Clinical Neuromuscular Disease
record_format MEDLINE/PubMed
spelling pubmed-74471712020-09-11 Longitudinal Analysis of Disease Burden in Refractory and Nonrefractory Generalized Myasthenia Gravis in the United States Harris, Linda Allman, Phillip H. Sheffield, Reinee Cutter, Gary J Clin Neuromuscul Dis Original Article OBJECTIVE: To compare temporal trends in clinical and health care resource utilization (HRU) outcomes in people with refractory and nonrefractory generalized myasthenia gravis (gMG). METHODS: A retrospective analysis of data from adults with gMG in the Myasthenia Gravis Foundation of America Patient Registry. gMG status (ever-refractory or always nonrefractory) and clinical (Myasthenia Gravis—Activities of Daily Living [MG-ADL] scores, exacerbations) and HRU outcomes were determined from questionnaires self-completed 6-monthly for up to 4 years. The probability of each outcome was compared for the 2 groups over time. RESULTS: The mean MG-ADL score and the probability of experiencing each outcome were significantly greater in the ever-refractory versus nonrefractory groups during each year of follow-up. Between-group differences in time trends were statistically significant for intensive care and feeding-tube use. CONCLUSIONS: People who have ever had refractory gMG may have worse functional status, more exacerbations, and higher HRU than people with consistently nonrefractory disease. Journal of Clinical Neuromuscular Disease 2020-09 2020-08-21 /pmc/articles/PMC7447171/ /pubmed/32833720 http://dx.doi.org/10.1097/CND.0000000000000301 Text en Copyright © 2020 The Author(s). Published by Wolters Kluwer Health, Inc. This is an open-access article distributed under the terms of the Creative Commons Attribution-Non Commercial-No Derivatives License 4.0 (CCBY-NC-ND) (http://creativecommons.org/licenses/by-nc-nd/4.0/) , where it is permissible to download and share the work provided it is properly cited. The work cannot be changed in any way or used commercially without permission from the journal.
spellingShingle Original Article
Harris, Linda
Allman, Phillip H.
Sheffield, Reinee
Cutter, Gary
Longitudinal Analysis of Disease Burden in Refractory and Nonrefractory Generalized Myasthenia Gravis in the United States
title Longitudinal Analysis of Disease Burden in Refractory and Nonrefractory Generalized Myasthenia Gravis in the United States
title_full Longitudinal Analysis of Disease Burden in Refractory and Nonrefractory Generalized Myasthenia Gravis in the United States
title_fullStr Longitudinal Analysis of Disease Burden in Refractory and Nonrefractory Generalized Myasthenia Gravis in the United States
title_full_unstemmed Longitudinal Analysis of Disease Burden in Refractory and Nonrefractory Generalized Myasthenia Gravis in the United States
title_short Longitudinal Analysis of Disease Burden in Refractory and Nonrefractory Generalized Myasthenia Gravis in the United States
title_sort longitudinal analysis of disease burden in refractory and nonrefractory generalized myasthenia gravis in the united states
topic Original Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7447171/
https://www.ncbi.nlm.nih.gov/pubmed/32833720
http://dx.doi.org/10.1097/CND.0000000000000301
work_keys_str_mv AT harrislinda longitudinalanalysisofdiseaseburdeninrefractoryandnonrefractorygeneralizedmyastheniagravisintheunitedstates
AT allmanphilliph longitudinalanalysisofdiseaseburdeninrefractoryandnonrefractorygeneralizedmyastheniagravisintheunitedstates
AT sheffieldreinee longitudinalanalysisofdiseaseburdeninrefractoryandnonrefractorygeneralizedmyastheniagravisintheunitedstates
AT cuttergary longitudinalanalysisofdiseaseburdeninrefractoryandnonrefractorygeneralizedmyastheniagravisintheunitedstates